Pelareorep Shows Durable Survival Benefit in Anal Cancer, Oncolytics Says
ONCY is trading near its 52-week low of $0.441 (4.7% above the low) on light trading volume (0.3× avg).
Summary
Oncolytics reported strong durability and survival data for pelareorep in anal cancer, and is pitching the drug as a potential backbone immunotherapy across HPV-driven cancers. That is a new tumor type for the story — prior updates centered on the REO 033 colorectal study and the GOBLET cohorts, so this widens the addressable case for the platform. The company is micro-cap and trading near its 52-week low, with going-concern language in the last 10-Q and an active $75M ATM, so a single positive dataset can move the stock sharply even though the release carries no numbers in the excerpt. What's missing is the actual magnitude: patient counts, response rates and duration figures are not in the headline or excerpt, and durability claims without a control arm are the kind of thing partners and the FDA will want quantified. Final GOBLET Cohort 4 results are expected in Q4 2026, with initial Cohort 5 data in H1 2027.
At the time of this announcement, ONCY was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.9M. The 52-week trading range was $0.44 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.